MEGAN SKRADIS: Open Payments
NPI 1750911020 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$557 in 25 payments from 12 companies in 2025. Trend: 2023 $669 · 2024 $462 · 2025 $557
Food & beverage: $557
| Company | Payments | Amount |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 6 | $176 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $82 |
| ABBVIE INC. | 3 | $68 |
| PFIZER INC. | 3 | $66 |
| Smith+Nephew, Inc. | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 2 | $28 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Merck Sharp & Dohme LLC | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Novo Nordisk Inc | 1 | $15 |
Products named: VOQUEZNA, CAPLYTA, PAXLOVID, QULIPTA, COLLAGENASE SANTYL, REXULTI, VRAYLAR, AZMIRO.
Industry payments across NE — which companies pay providers there.
